Abstract: Animal feed conversion ratio can be increased and blood glucose levels can be decreased by feeding an efficacious amount of dispersible amorphous poly(3-hydroxybutyrate/3-hydroxyvalerate).

Abstract: The invention provides compositions and methods for the treatment of glomerulonephritis. In one embodiment, the invention provides a compound of formula (I) R-L-CO—X??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) or a salt thereof for use in the treatment of glomerulonephritis.

Abstract: A fire ant killer chemical composition (the “FAK Composition”) for effective killing of fire ants where the FAK Composition utilizes a minimal amount of active ingredients thereby significantly reducing safety concerns with respect to the use of said active ingredients, the FAK composition having a dish detergent composition and an insecticide composition.

Abstract: The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: The present invention relates to a synthetic compound and its therapeutic uses.

Abstract: The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a method for application of malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and which can be encountered in the air, on textiles, bathroom or kitchen surfaces, and the like. The composition may be applied as is or in the form of a perfuming composition or in a consumer product or article containing the compound or perfume composition.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: The present application relates to personal care compositions including perfumes and sulfur-based perfume raw materials, and methods for making and using the personal care compositions to resist consumer fragrance habituation.

Abstract: A ribose-related compound is added to whole blood or packed red cells which have suboptimal function as measured by decreased levels of 2,3-DPG in order to rejuvenate the red blood cells to normal function as seen by raised levels of 2,3-DPG. Two representative ribose-related compounds are D-ribose and inosine.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: The present invention is directed to a novel compound, 2-mercapto-5-methyl-4-heptanone, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a medicinal product, and toothpaste comprising the step of incorporating an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone, and a process of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone.

Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides.

Abstract: A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin.

Abstract: An inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process including the control of the pH in the initial aqueous phase; Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.

Abstract: Compositions and methods for controlling and/or repelling bedbugs are provided. The compositions comprise one or more compounds having bedbug repellant activity. Such compounds may be, for example, naturally occurring semiochemicals or structural or functional analogs of naturally occurring semiochemicals. Exemplary compounds are compounds of general formula (I).

Abstract: In one aspect, there is provided heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof for use as a local anaesthetic. In another aspect, there is provided a pharmaceutical composition comprising heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof and one or more pharmaceutically acceptable carriers, excipients or diluents. Also provided is use of heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof in the preparation of a medicament for use as a local anaesthetic. Further provided is a method of treating a mammalian subject in need of local anaesthesia, comprising administering a pharmaceutical composition comprising heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof in an effective amount to a region of the subject in need of local anaesthesia.

Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.

Abstract: This invention provides antimicrobial compositions containing methylglyoxal and material with methylglyoxal contained (such as manuka honey). The antimicrobial activity of methylglyoxal, or material with a methylglyoxal presence, is maintained and/or enhanced by mixing methylglyoxal or material with a methylglyoxal presence with cyclodextrin. Methods of preparing such compositions, including powder composition, and methods of using such compositions are also provided.

Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.

Abstract: Antimicrobial mixtures comprising or consisting of: one or more branched or unbranched alkanediols having 6-12 carbon atoms, one, two or more compounds chosen from the group consisting of the tropolones of the formula (I) wherein the substituents R1, R2, R3, R4 and R5 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR6, wherein R6 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR7, wherein R7 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO2; NH2; F, Cl, Br, I; are described.

Abstract: The present invention provides methods and compositions for treating cancer metastasis by cyclohexenone compounds.

Abstract: The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ10, natural Omega-3 fatty acids, natural bioflavonoids, natural vitamin E, amino acids and derivatives thereof, minerals, extra virgin olive oil, lecithin, B-complex vitamins, and antioxidants.

Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.

Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.

Abstract: A description is given of (4-haloalkyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, Y, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.

Abstract: Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C16-24 unsaturated hydrocarbon group optionally interrupted by ?, ?, ?, or ? to the carbonyl group by a heteroatom or group of heteroatoms selected from S, O, N, SO, SO2 said hydrocarbon group comprising at least 5 non-conjugated double bonds; and X is an electron withdrawing group) in the manufacture of a medicament for the treatment of psoriasis.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.

Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant Phaleria macrocarpa (Scheff.) Boerl. The invention also relates to the use of said compounds, either as a single active compound or in combination, in a pharmaceutical dosage form that has anti-proliferative activity of cancer cells, and its use relating to female related diseases. Formula (I).

Abstract: A description is given of (4-trifluoromethyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of a transdermal patch. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones is from 10 to 16 carbon atoms and method for achieving such control or repellency.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: A compound of formula (I) R-L-CO—X ??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) for use in the treatment of rheumatoid arthritis.

Abstract: A bacterial autoinducer, CAI-1, was purified and its structure identified. Methods for synthesis of the autoinducer and its analogues were elucidated. Methods of using the autoinducer or its analogues for treating bacterial pathogenicity and bio film formation are described. Methods for prevention and treatment of cholera are described. Synthetic (S)-3-hydroxytridecan-4-one functions as well as natural CAI-1 in repressing production of the virulence factor toxin co-regulated pilus (TCP). Strategies are described to manipulate bacterial quorum sensing in the clinical arena.

Abstract: Process for the preparation of a composition including an oil phase, an aqueous phase, at least one emulsifying system of water-in-oil (W/O) type, optionally at least one emulsifying system of oil-in-water (O/W) type, in the form of an inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process being characterized in that the preparation of the aqueous phase includes the dissolution in the aqueous medium of solid 2-acrylamido-2-methyl propanesulfonic acid before neutralization. Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process.

Abstract: Radiation-oxidative exposure treatment compositions may include a mixture of micronutrient multivitamin and trace elements, a mixture of antioxidants and chemopreventative agents, and optionally a mixture of fatty acids. Methods of treatment of a subject exposed to a radiation source or an oxidative stress with the radiation-oxidative exposure treatment composition may include the step of administering to the subject a daily dose of the radiation-oxidative exposure treatment composition such that the life shortening effects induced by the radiation source or the oxidative stress are ameliorated.

Abstract: The invention relates to the use of a composition comprising at least one volatile molecule specific to the estrus of cows in order to improve the reproductive function of a bull. In particular, the composition according to the invention makes it possible to act on the libido of the bull, but also on the production of semen by the bull. Preferably, the composition used comprises at least one molecule from among coumarin, squalene, 6-amino undecane, 2-butanone, 9-octadecenoic acid and 1,2-dichloroethylene.

Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.

Abstract: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or thionate compounds and/or any chemical species capable of providing to a subject in need thereof a sulfide compound, thiosulfate compound, thionite compound, or thionate compound. The unique compositions of this invention contain one or more “active sulfur substances” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic substances. In particular, a novel method of combining active ingredient with wet cellulose is provided, which allows the wet cellulose to function as an enteric carrier.

Abstract: A method for treating hepatitis C virus infection with a composition containing quercetin, together with one or more of vitamin B3, vitamin C, a folate compound. Also disclosed is a method for treating conditions associated with an elevated level of heat shock proteins, including liver cancer, using the above-mentioned composition.

Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.